×
SIGN UP FOR OUR MONTHLY NEWSLETTER

The cost of this growing condition to patients and practices

While it was once perceived as a minor irritation, today dry eye disease (DED) is considered a “critical and significant public health issue” in the U.S., according to the Ophthalmology Times. An estimated 16 million Americans have been diagnosed with DED, but the actual number of people affected is much higher. Some studies show that nearly half of all U.S. adults experience dry eye signs and symptoms, which include watery, itchy, or burning eyes, sensitivity to light, and blurred vision—significantly impacting their quality of life. Read More

A patented in-office procedure plus at-home care gives patients relief from this common condition

Blepharitis is one of the most common eye conditions, and yet it is one of the most under-diagnosed. Why? First, like dry eye or allergies, blepharitis symptoms can be mild or easily mistaken for other issues. So patients may dismiss symptoms, not knowing there’s a name or treatment for what they’re experiencing. Second, blepharitis—by definition, inflammation of the eyelids—often isn’t diagnosed until it is severe, which involves debris or discharge on the lashes.  Read More

Be proactive about patient intakes and screening to identify those at risk

In July, the U.S. Congress passed legislation to extend coverage of health care costs for rescue workers and victims of the Sept. 11, 2001, terrorist attacks. The bill will fund all current and future medical claims from 9/11 survivors through 2092, as well as residents who lived near the World Trade Center in New York City, the Pentagon in Washington, D.C., and Shanksville, Pa., where United Flight 93 crashed, reported the Wall Street JournalRead More

Making glaucoma medications easier and more affordable

Eyecare practitioners have several options for the drugs we prescribe to patients. First and generally most expensive, there are the branded, proprietary, patented drugs such as Xiidra, Rocklatan, and Vyzulta. Then there are generics—both branded generics and generics with equivalent active ingredients such as latanoprost, which are much less costly to insurance companies and patients. Read More

A drug for acute NAION is currently in phase III clinical trials

After glaucoma, the second-most common source of optic nerve damage is Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). We usually describe this to a patient as a “stroke in the eye,” where blood supply to the optic nerve is cut off due to conditions ranging from hypotension to carotid occlusive disease. This condition typically causes sudden and acute vision loss in one eye, without any pain. Some patients get marginal improvement with time, but usually the prognosis is poor. Read More